AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks

AstraZeneca (AZN) has dropped 19.5% over the past six months following a string of pipeline setbacks. Clinical failures for Wainua and Ultomiris, coupled with FDA delays for camizestrant, have pressured shares despite the company's broader portfolio strength.

AZN maintains 16 blockbuster drugs and posted 15% oncology sales growth. Management is targeting $80 billion in revenues by 2030, supported by plans to launch 20 new medicines. Zacks Investment Research recommends staying invested, citing these growth prospects even as patent expirations and China market uncertainty present headwinds.

The sharp pullback follows concrete regulatory and clinical stumbling blocks that have raised questions about near-term catalysts. However, the oncology franchise continues to deliver double-digit growth, and the 2030 revenue target implies significant expansion from current levels. The tension between recent setbacks and long-term pipeline ambition defines the current risk-reward setup.